Press releases

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

Regulatory

May 26, 2021

Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Wednesday, 26 May 2021. At the Annual General Meeting, the following principal resolutions were passed.

Read more

Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021

Regulatory

May 26, 2021

A strong start for PEPAXTO in the US

Read more

Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma

Regulatory

May 25, 2021

· According to the Independent Review Committee Assessment, melflufen was non-inferior to pomalidomide on the primary endpoint of Progression Free Survival (PFS) with a Hazard Ratio favoring melflu...

Read more

Invitation to presentation of the Q1 2021 results

May 20, 2021

STOCKHOLM — May 20, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish...

Read more

Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology

May 19, 2021

STOCKHOLM — May 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announ...

Read more

Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting

May 12, 2021

STOCKHOLM — May 12, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announ...

Read more

Oncopeptides completes patient enrollment in phase 2 PORT study

May 5, 2021

STOCKHOLM — May 5, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announc...

Read more

Number of shares and votes in Oncopeptides

Regulatory

April 30, 2021

Stockholm — April 30, 2021 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed due to the directed issue of 7,000,000 shares, whi...

Read more

Oncopeptides publishes the 2020 Annual Report

Regulatory

April 26, 2021

STOCKHOLM — April 26, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today publ...

Read more

Annual General Meeting in Oncopeptides AB (publ)

Regulatory

April 26, 2021

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annua...

Read more

Oncopeptides submits application for conditional marketing authorization of melflufen in the EU

Regulatory

April 16, 2021

STOCKHOLM — April 16, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today anno...

Read more

Number of shares and votes in Oncopeptides

Regulatory

March 31, 2021

Stockholm — March 31, 2021 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants under the company’...

Read more

Oncopeptides announces that PEPAXTO® is included in new Multiple Myeloma guidelines of National Comprehensive Cancer Network®

March 22, 2021

STOCKHOLM — March 22, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today anno...

Read more

Oncopeptides announces that the first patients in the United States are being treated with PEPAXTO®

March 15, 2021

STOCKHOLM — March 15, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today anno...

Read more

Oncopeptides has completed a directed share issue raising approximately SEK 1,106 million (USD 130 million)

Regulatory

March 10, 2021

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRI...

Read more

Oncopeptides intends to carry out a directed share issue

Regulatory

March 9, 2021

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRI...

Read more

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma

March 8, 2021

STOCKHOLM — March 8, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today annou...

Read more

FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma

Regulatory

February 26, 2021

STOCKHOLM — February 26, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today a...

Read more

YEAR-END REPORT 2020

Regulatory

February 18, 2021

Summary Q4

Read more